Samsca is owned by Otsuka.
Samsca contains Tolvaptan.
Samsca has a total of 2 drug patents out of which 0 drug patents have expired.
Samsca was authorised for market use on 19 May, 2009.
Samsca is available in tablet;oral dosage forms.
The generics of Samsca are possible to be released after 07 April, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(7 years from now) |
Drugs and Companies using TOLVAPTAN ingredient
Market Authorisation Date: 19 May, 2009
Treatment: NA
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic